Resources from the same session
Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma
Presenter: Caroline Robert
Session: Melanoma and other skin tumours
Resources:
Abstract
Presentation
Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma
Presenter: Rajat Rai
Session: Melanoma and other skin tumours
Resources:
Abstract
Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma
Presenter: Patrick Hwu
Session: Melanoma and other skin tumours
Resources:
Abstract
PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis
Presenter: Georgina Long
Session: Melanoma and other skin tumours
Resources:
Abstract
Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)
Presenter: Paolo Ascierto
Session: Melanoma and other skin tumours
Resources:
Abstract
Presentation
Invited discussant LBA39, LBA40 and abstract 1111O
Presenter: Céleste Lebbé
Session: Melanoma and other skin tumours
Resources:
Presentation
Invited discussant abstracts 1108PD, 1109PD and 1110PD
Presenter: Axel Hauschild
Session: Melanoma and other skin tumours
Resources:
Presentation
Webcast
Invited discussant abstracts 1106O and 1107O
Presenter: Olivier Michielin
Session: Melanoma and other skin tumours
Resources:
Presentation
Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma
Presenter: Jason Chesney
Session: Melanoma and other skin tumours
Resources:
Abstract
Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone
Presenter: Antoni Ribas
Session: Melanoma and other skin tumours
Resources:
Abstract
Presentation